Inhibiting the HIV Integration Process: Past, Present, and the Future

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2013 Sep 13

PMID 24025027

Citations 35

Authors

Roberto Di Santo

Affiliations

Soon will be listed here.

Abstract

HIV integrase (IN) catalyzes the insertion into the genome of the infected human cell of viral DNA produced by the retrotranscription process. The discovery of raltegravir validated the existence of the IN, which is a new target in the field of anti-HIV drug research. The mechanism of catalysis of IN is depicted, and the characteristics of the inhibitors of the catalytic site of this viral enzyme are reported. The role played by the resistance is elucidated, as well as the possibility of bypassing this problem. New approaches to block the integration process are depicted as future perspectives, such as development of allosteric IN inhibitors, dual inhibitors targeting both IN and other enzymes, inhibitors of enzymes that activate IN, activators of IN activity, as well as a gene therapy approach.

Citing Articles

Exploring the potential of some natural indoles as antiviral agents: quantum chemical analysis, inverse molecular docking, and affinity calculations.

Belal A, Abdou A, Miski S, Ali M, Ghamry H, Obaidullah A Front Chem. 2025; 12:1521298.

PMID: 39886558 PMC: 11779707. DOI: 10.3389/fchem.2024.1521298.

Quinolinonyl Derivatives as Dual Inhibitors of the HIV-1 Integrase Catalytic Site and Integrase-RNA interactions.

Patacchini E, Madia V, Albano A, Ruggieri G, Messore A, Ialongo D ACS Med Chem Lett. 2024; 15(9):1533-1540.

PMID: 39291012 PMC: 11403752. DOI: 10.1021/acsmedchemlett.4c00268.

Structure-Based Design of Novel Thiazolone[3,2-]pyrimidine Derivatives as Potent RNase H Inhibitors for HIV Therapy.

Zhu X, Corona A, Maloccu S, Tramontano E, Wang S, Pannecouque C Molecules. 2024; 29(9).

PMID: 38731613 PMC: 11085872. DOI: 10.3390/molecules29092120.

Elucidating the Molecular Determinants of the Binding Modes of a Third-Generation HIV-1 Integrase Strand Transfer Inhibitor: The Importance of Side Chain and Solvent Reorganization.

Sun Q, Biswas A, Lyumkis D, Levy R, Deng N Viruses. 2024; 16(1).

PMID: 38257776 PMC: 11154245. DOI: 10.3390/v16010076.

Elucidating the molecular determinants for binding modes of a third-generation HIV-1 integrase strand transfer inhibitor: Importance of side chain and solvent reorganization.

Sun Q, Biswas A, Lyumkis D, Levy R, Deng N bioRxiv. 2023; .

PMID: 38077045 PMC: 10705364. DOI: 10.1101/2023.11.29.569269.

References

Oz Gleenberg I, Herschhorn A, Hizi A . Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). J Mol Biol. 2007; 369(5):1230-43. DOI: 10.1016/j.jmb.2007.03.073. View

Dyda F, Hickman A, Jenkins T, Engelman A, Craigie R, Davies D . Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science. 1994; 266(5193):1981-6. DOI: 10.1126/science.7801124. View

Wiech N, Fisher J, Helquist P, Wiest O . Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders. Curr Top Med Chem. 2009; 9(3):257-71. DOI: 10.2174/156802609788085241. View

Vandekerckhove L, Christ F, Van Maele B, De Rijck J, Gijsbers R, Van den Haute C . Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J Virol. 2006; 80(4):1886-96. PMC: 1367129. DOI: 10.1128/JVI.80.4.1886-1896.2006. View

Grewe B, Uberla K . The human immunodeficiency virus type 1 Rev protein: ménage à trois during the early phase of the lentiviral replication cycle. J Gen Virol. 2010; 91(Pt 8):1893-1897. DOI: 10.1099/vir.0.022509-0. View

Karki R, Tang Y, Burke Jr T, Nicklaus M . Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design. J Comput Aided Mol Des. 2005; 18(12):739-60. DOI: 10.1007/s10822-005-0365-5. View

Wang Z, Bennett E, Wilson D, Salomon C, Vince R . Rationally designed dual inhibitors of HIV reverse transcriptase and integrase. J Med Chem. 2007; 50(15):3416-9. DOI: 10.1021/jm070512p. View

Hayouka Z, Levin A, Maes M, Hadas E, Shalev D, Volsky D . Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370. Biochem Biophys Res Commun. 2010; 394(2):260-5. DOI: 10.1016/j.bbrc.2010.02.100. View

Al-Mawsawi L, Al-Safi R, Neamati N . Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs. 2008; 13(2):213-25. DOI: 10.1517/14728214.13.2.213. View

10.

Kaushik N, Rege N, Yadav P, Sarafianos S, Modak M, Pandey V . Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase. Biochemistry. 1996; 35(36):11536-46. DOI: 10.1021/bi960364x. View

11.

Ammar F, Abdel-Azeim S, Zargarian L, Hobaika Z, Maroun R, Fermandjian S . Unprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravir. PLoS One. 2012; 7(7):e40223. PMC: 3388078. DOI: 10.1371/journal.pone.0040223. View

12.

Maertens G, Cherepanov P, Engelman A . Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. J Cell Sci. 2006; 119(Pt 12):2563-71. DOI: 10.1242/jcs.02995. View

13.

Agapkina J, Smolov M, Zubin E, Mouscadet J, Gottikh M . HIV-1 integrase can process a 3'-end crosslinked substrate. Eur J Biochem. 2003; 271(1):205-11. DOI: 10.1046/j.1432-1033.2003.03921.x. View

14.

Copeland R, Pompliano D, Meek T . Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006; 5(9):730-9. DOI: 10.1038/nrd2082. View

15.

Lin Z, Neamati N, Zhao H, Kiryu Y, Turpin J, Aberham C . Chicoric acid analogues as HIV-1 integrase inhibitors. J Med Chem. 1999; 42(8):1401-14. DOI: 10.1021/jm980531m. View

16.

Demeulemeester J, Tintori C, Botta M, Debyser Z, Christ F . Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors. J Biomol Screen. 2012; 17(5):618-28. DOI: 10.1177/1087057111436343. View

17.

Tintori C, Demeulemeester J, Franchi L, Massa S, Debyser Z, Christ F . Discovery of small molecule HIV-1 integrase dimerization inhibitors. Bioorg Med Chem Lett. 2012; 22(9):3109-14. DOI: 10.1016/j.bmcl.2012.03.064. View

18.

Chandrasekhar K, Malathhi R . Non-Watson Crick base pairs might stabilize RNA structural motifs in ribozymes -- a comparative study of group-I intron structures. J Biosci. 2003; 28(5):547-55. DOI: 10.1007/BF02703330. View

19.

Goldgur Y, Dyda F, Hickman A, Jenkins T, Craigie R, Davies D . Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc Natl Acad Sci U S A. 1998; 95(16):9150-4. PMC: 21307. DOI: 10.1073/pnas.95.16.9150. View

20.

Nowotny M, Yang W . Stepwise analyses of metal ions in RNase H catalysis from substrate destabilization to product release. EMBO J. 2006; 25(9):1924-33. PMC: 1456928. DOI: 10.1038/sj.emboj.7601076. View